{
  "@context": {
    "dct": "http://purl.org/dc/terms/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfa": "http://www.w3.org/ns/rdfa#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "schema": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "schema:DrugPregnancyCategory",
      "@type": "rdfs:Class",
      "rdfs:comment": "Categories that represent an assessment of the risk of fetal injury due to a drug or pharmaceutical used as directed by the mother during pregnancy.",
      "rdfs:label": "DrugPregnancyCategory",
      "rdfs:subClassOf": {
        "@id": "schema:MedicalEnumeration"
      },
      "schema:isPartOf": {
        "@id": "http://health-lifesci.schema.org"
      }
    },
    {
      "@id": "schema:FDAcategoryD",
      "@type": "schema:DrugPregnancyCategory",
      "rdfs:comment": "A designation by the US FDA signifying that there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.",
      "rdfs:label": "FDAcategoryD",
      "schema:isPartOf": {
        "@id": "http://health-lifesci.schema.org"
      }
    }
  ]
}